- Classification of acute myeloid leukemia
-
Hwang SM
- KMID: 2504735
- Blood Res.
- 2020 Jul;55(S1):S1-S4.
- doi: 10.5045/br.2020.S001
The World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues was revised in 2017 on the basis of recent high-throughput sequencing and gene expression data on hematologic... -
- CITED
-
- Close
- SHARE
-
- Close
- New agents in acute myeloid leukemia (AML)
-
Park S, Cho BS, Kim HJ
- KMID: 2504737
- Blood Res.
- 2020 Jul;55(S1):S14-S18.
- doi: 10.5045/br.2020.S003
Despite expanding knowledge in the molecular landscape of acute myeloid leukemia (AML) and an increasing understanding of leukemogenic pathways, little has changed in the treatment of AML in the last... -
- CITED
-
- Close
- SHARE
-
- Close
- AL amyloidosis: advances in diagnosis and management
-
Koh Y
- KMID: 2504743
- Blood Res.
- 2020 Jul;55(S1):S54-S57.
- doi: 10.5045/br.2020.S009
Light chain (AL) amyloidosis is a disease in which malignant plasma cell clones affect multiple organs including the heart and kidney. The mechanism for organ function deterioration in AL amyloidosis... -
- CITED
-
- Close
- SHARE
-
- Close
- Extranodal NK/T cell lymphoma
-
Jeong SH
- KMID: 2504745
- Blood Res.
- 2020 Jul;55(S1):S63-S71.
- doi: 10.5045/br.2020.S011
Extranodal natural killer (NK)/T cell lymphoma (ENKTL) is a distinct subtype of Non-Hodgkin’s lymphoma mainly involving the nasal area. Since the entity was first recognized, treatment strategies have been evolving... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent advances in chronic lymphocytic leukemia therapy
-
Uhm J
- KMID: 2504746
- Blood Res.
- 2020 Jul;55(S1):S72-S82.
- doi: 10.5045/br.2020.S012
Chronic lymphocytic leukemia is a genetically heterogeneous disease, and a complex set of genetic alterations is associated with its pathogenesis. CLL is the most common leukemia in the western countries,... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatments for children and adolescents with AML
-
Kim H
- KMID: 2504736
- Blood Res.
- 2020 Jul;55(S1):S5-S13.
- doi: 10.5045/br.2020.S002
In recent decades, survival rates for childhood acute myeloid leukemia have remarkably improved, owing to chemotherapy intensification, allogeneic hematopoietic stem cell transplantation, and improved supportive care. Furthermore, treatment protocols have... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent advances in the management of primary central nervous system lymphoma
-
Choi YS
- KMID: 2504744
- Blood Res.
- 2020 Jul;55(S1):S58-S62.
- doi: 10.5045/br.2020.S010
Primary central nervous system lymphoma (PCNSL) is a rare subtype of extranodal lymphoma primarily involving the brain, spinal cord, or leptomeninges. PCNSL is associated with a relatively poor prognosis compared... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment of relapsed and refractory multiple myeloma
-
Lee JH, Kim SH
- KMID: 2504742
- Blood Res.
- 2020 Jul;55(S1):S43-S53.
- doi: 10.5045/br.2020.S008
The therapeutic strategy for relapsed and refractory multiple myeloma (RRMM) integrates a holistic approach regarding patient, disease, and drug-related factors. Patient-related factors include age, frailty status, and underlying comorbidities, especially... -
- CITED
-
- Close
- SHARE
-
- Close
- Optimal therapy for adolescents and young adults with acute lymphoblastic leukemia-current perspectives
-
Lee JW
- KMID: 2504739
- Blood Res.
- 2020 Jul;55(S1):S27-S31.
- doi: 10.5045/br.2020.S005
Adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) have worse prognosis than children. Differing biology of ALL may account for some of this disparity in outcome, with AYA... -
- CITED
-
- Close
- SHARE
-
- Close
- Frontline therapy for newly diagnosed patients with multiple myeloma
-
Jung SH, Jo JC, Song GY, Ahn SY, Yang DH, Ahn JS, Kim HJ, Lee JJ
- KMID: 2504741
- Blood Res.
- 2020 Jul;55(S1):S37-S42.
- doi: 10.5045/br.2020.S007
Since the introduction of an alkylator to the treatment of multiple myeloma (MM), new effective agents have been developed, such as immunomodulatory drugs including thalidomide, lenalidomide, and pomalidomide; proteasome inhibitors... -
- CITED
-
- Close
- SHARE
-
- Close
- Minimal residual disease in acute lymphoblastic leukemia: technical aspects and implications for clinical interpretation
-
Kim IS
- KMID: 2504738
- Blood Res.
- 2020 Jul;55(S1):S19-S26.
- doi: 10.5045/br.2020.S004
Minimal residual disease (MRD) monitoring has proven to be one of the fundamental independent prognostic factors for patients with acute lymphoblastic leukemia (ALL). Sequential monitoring of MRD using sensitive and... -
- CITED
-
- Close
- SHARE
-
- Close
- Current treatment strategies for Philadelphia chromosome-positive adult acute lymphoblastic leukemia
-
Park HS
- KMID: 2504740
- Blood Res.
- 2020 Jul;55(S1):S32-S36.
- doi: 10.5045/br.2020.S006
Acute lymphoblastic leukemia (ALL) is an aggressive hematological disease. The incorporation of tyrosine kinase inhibitors (TKIs) into the standard treatment regimen for Philadelphia (Ph)-positive ALL significantly improved clinical outcomes. TKI-based... -
- CITED
-
- Close
- SHARE
-
- Close
